Article
Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients.
Cancer chemotherapy and pharmacology - 1 Jun 2023
Groenland Stefanie L, Janssen J M, Nijenhuis C M, de Vries N, Rosing H, Wilgenhof S, van Thienen J V, Haanen J B A G, Blank C U, Beijnen J H, Huitema A D R, Steeghs N
Abstract excerpt
INTRODUCTION: Dabrafenib and trametinib are currently administered at fixed doses, at which interpatient variability in exposure is high. The aim of this study was to investigate whether drug exposure is related to efficacy and toxicity in a real-life cohort of melanoma patients treated with dabrafenib plus trametinib. PATIENTS AND METHODS: An observational study was performed in which pharmacokinetic samples...
Topics
Join the communities discussing this publication.